FERNANDO
PÉREZ RUIZ
University of Texas Southwestern Medical Center
Dallas, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Texas Southwestern Medical Center (1)
2017
-
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study
Annals of the Rheumatic Diseases, Vol. 76, Núm. 10, pp. 1679-1687